Imaxio announces the first human clinical trial using its pro-immunogenic technology IMX313, in tuberculosis

IMX313, Imaxio’s antigen re-engineering technology, has been administrated for the first time in humans as part of a tuberculosis vaccine phase I clinical trial managed by the Jenner Institute at Oxford University.